Bioequivalence Study of Gefitinib Tablets Under Fed Conditions

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The study design is an Open-Label,Randomized, Single-Dose, 2-way Crossover Bioequivalence Study. During each session, the subjects will be administered a single dose of 250mg Gefitinib Tablet (one Gefitinib Tablet 250mg of Hunan Kelun or one Iressa® Tablet 250mg of AstraZeneca) under fed conditions.
Epistemonikos ID: a33e4e9a75dd580f5ad14c7bced0da3dd2d88007
First added on: May 20, 2024